Companies STORM Therapeutics

First-in-class therapies targeting RNA modifying enzymes


STORM Therapeutics pioneering founders have led the discovery of the role that RNA modifying enzymes play in a variety of diseases, including cancer and viral infection.

Cambridge Innovation Capital is a leading Series A investor in the Cambridge ecosystem.

We were born out of a unique relationship with the University of Cambridge and we maintain privileged access to its most inspiring ideas and people in life sciences and deep tech.

Discover more


Read More